Key Takeaways Gilead posted 3% year-over-year revenue growth in Q3 2025, led by higher product and royalty revenues.HIV drugs Biktarvy and Descovy fueled gains, while Livdelzi lifted liver disease portfolio sales by 12%.Veklury and Cell Therapy sales declined, but Yeztugo's early uptake and patent wins support future growth.Gilead Sciences, Inc.’s (GILD) posted 3% year-over-year growth in total revenues for the third quarter of 2025.Total revenues comprise product sales and royalty, contract and other reven ...